title: Bisphosphonates and metastatic bone disease.
authors.affiliation: Division of Medical Oncology, Treviglio Hospital, Treviglio, Italy. sandro.barni@ospedale.treviglio.bg.it
authors.forename: S
authors.initials: S
authors.lastname: Barni
authors.forename: M
authors.initials: M
authors.lastname: Mandalà
authors.forename: M
authors.initials: M
authors.lastname: Cazzaniga
authors.forename: M
authors.initials: M
authors.lastname: Cabiddu
authors.forename: M
authors.initials: M
authors.lastname: Cremonesi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004164:Diphosphonates / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced; D008495:Medical Oncology; D009362:Neoplasm Metastasis / Q000517:prevention & control; D010014:Osteolysis / Q000188:drug therapy; D010020:Osteonecrosis / Q000139:chemically induced; D010026:Osteosclerosis / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates